Cancer Chemotherapy and Pharmacology

, Volume 31, Issue 3, pp 171–181 | Cite as

A review of the stability and compatibility of antineoplastic drugs for multiple-drug infusions

  • David A. Williams
  • Jacob Lokich
Review Antineoplastic Drugs, Multiple Drug Infusion

Summary

It is important that the stability of reconstituted parenteral antineoplastic agents be established, particularly in the context of ambulatory infusion systems for delivery. The stability of selected agents within each of the five classes of compounds (antimetabolites, alkylating agents, antibiotics, alkaloids and glycosides, and metals) is reviewed from the literature together with additional data from studies carried out using high-performance liquid chromatographic (HPLC) technology in clinically applicable volumes and concentrations for ambulatory infusion. The stability of reconstituted drugs varies from a few minutes (mecloethamine) to many months (FU). Compatibility data on two- and three-drug admixtures of cytotoxic agents are reported for a number of common multidrug regimens. Tabular presentation of the drug-drug compatibilities and incompatibilities is included along with a discussion of the mechanisms for drug-drug interaction. The use of a broad spectrum of compatible cytotoxic drugs is possible, including fluoropyrimidine-, anthracycline-, and platinum-based combinations, providing the capability of carrying out multidrug infusions for 4–7 days in an ambulatory delivery system.

Keywords

Cancer Research Delivery System Alkaloid Glycoside Broad Spectrum 

Abbreviations

CBP

carboplatin

CDDP

cisplatin

CP

cyclophosphamide

DTC

decarbazine

DX

doxorubicin

D5W

dextrose for injection

FU

fluorouracil

FUDR

floxuridine

IF

ifosfamide

LV

leucovorin

MMC

mitomycin C

MTX

methotrexate

NS

sodium chloride for injection

R

Ringer's injection

SW

sterile water

VP16

etoposide

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams PS, Haines-Nutt RF, Bradford E, Palmer A, Rowland CB (1987) Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J April 11: 476–478Google Scholar
  2. 2.
    Allsopp M, Sewell GJ, Rowland C, Riley CM, Schowen RL (1991) The degradation of carboplatin in aqueous solutions containing chloride or other nucleophiles. Int J Pharm 69: 197–210Google Scholar
  3. 3.
    Anderson N, Lokich J, Bern M, Wallach S, Moore C, Williams D (1989) A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Cancer 63:233–237Google Scholar
  4. 4.
    Anderson N, Lokich J, Bern M, Wallach S, Moore C, Williams D, Umprayn V (1989) Combined 5-fluorouracil and floxuridine administered as a 14-day infusion. Cancer 63:825–827Google Scholar
  5. 5.
    Bayoni SM, Al-Badr AA (1989) Fluorouracil. In: Florey K (ed) Analytical profiles of drug substances, vol 18. Academic Press, New York, pp 599–639Google Scholar
  6. 6.
    Behme RJ, Brooke D, Kensler TT, Scott JA (1988) Incompatibility of ifosfamide with benzyl alcohol preserved bacteriostatic water for injection. Am J Hosp Pharm 45: 627–628Google Scholar
  7. 7.
    Beijnen JH, Rosing H, Vries PA de, Underberg WJM (1985) Stability of anthracycline antitumor agents in infusion fluids. J Parenter Sci Technol 39: 220–222Google Scholar
  8. 8.
    Beijnen JH, Houwen OAGJ van der, Underberg WJM (1986) Aspects of the degradation kinetics of doxorubicin in aqueous solution. Int J Pharm 32: 123–131Google Scholar
  9. 9.
    Beijnen JH, Houwen OAGJ van der, Voskuilen MCH, Underberg WJM (1986) Aspects of the degradation kinetics of daunorubicin in aqueous solution. Int J Pharm 31: 75–82Google Scholar
  10. 10.
    Beijnen JH, Lingeman H, Van Munster HA, Underberg WJM (1986) Mitomycin antitumour agents: a review of their physico-chemical and analytical properties and stability. J Pharm Biomed Anal 4: 275–295Google Scholar
  11. 11.
    Beijnen JH, Neef C, Meuwissen OJAT, Rutten JMH, Rosing H, Underberg WJM (1986) Stability of intravenous mixtures of doxorubicin and vincristine. Am J Hosp Pharm 43: 3022–3026Google Scholar
  12. 12.
    Beijnen JH, Bult A, Underberg WJM (1987) Mitomycin C. In: Florey K (ed) Analytical profiles of drug substances, vol 16. Academic Press. New York, pp 361–401Google Scholar
  13. 13.
    Beijnen JH, Bult A, Underberg WJM (1988) Mitoxanthrone hydrochloride. In: Florey K (ed) Analytical profiles of drug substances, vol 17. Academic Press, New York, pp 221–258Google Scholar
  14. 14.
    Beijnen JHM, Vendrig DEMM, Underberg WJM (1988) Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. J Parenter Sci Technol 43: 84–87Google Scholar
  15. 15.
    Beijnen JH, Holthuis JJM, Kerkdijk HG, Paalman ACA, Bult A, Underberg WJM (1988) Degradation kinetics of etoposide in aqueous solution. Int J Pharm 41: 169–178Google Scholar
  16. 16.
    Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL (1981) Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 38: 1914–1918Google Scholar
  17. 17.
    Benvenuto JA, Adams SC, Vyas HM, Anderson RW (1987) Pharmaceutical issues in infusion chemotherapy stability and compatibility. In: Lokich J (ed) Cancer chemotherapy by infusion, 1st edn. Precept, Chicago, pp 100–113Google Scholar
  18. 18.
    Bosanquet AG (1986) Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays: Adriamycin and other antitumour antibiotics. Cancer Chemother Pharmacol 17: 1–10Google Scholar
  19. 19.
    Brooke D, Bequette RJ, Davis RE (1973) Chemical stability of cyclophosphamide in parenteral solutions. Am J Hosp Pharm 30: 134–137Google Scholar
  20. 20.
    Carter SK, Crooke ST (1979) Mitomycin C: current status and new developments. Academic Press, New YorkGoogle Scholar
  21. 21.
    Cheung Y-W, Cradock JC, Vishnuvajjala BR, Flora KP (1987) Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm 44: 124–130Google Scholar
  22. 22.
    Connors KA, Amidon GL, Stella VJ (1986) Chemical stability of pharmaceuticals: a handbook for pharmacists, 2nd edn. J Wiley & Sons New YorkGoogle Scholar
  23. 23.
    Dine T, Luyckx M, Cazin JC, Buenet C, Cazin M, Goudaliez F, Mallevais ML (1991) Stability and compatibility of vinblastine, vincristine, vindesine, and vinorelbine with PVC infusion bags. Int J Pharm 77: 279–285Google Scholar
  24. 24.
    Dorr RT, Fritz WL (1980) Drug data sheets: Bleomycin sulfate. In: Dorr RT, Fritz WL (eds) Cancer chemotherapy handbook. Elsevier, New York, pp 274–283Google Scholar
  25. 25.
    Dyvik O, Grislingaas AL, Tonnesen HH, Karlsen J (1986) Methotrexate in infusion solutions — stability test for the hospital pharmacy. J Clin Hosp Pharm 11: 343–348Google Scholar
  26. 26.
    Hansen J, Kreilgard B, Nielson O, Vege J (1983) Kinetics of degradation of methotrexate in aqueous solution. Int J Pharm 16: 141Google Scholar
  27. 27.
    Holthuis JJM, Kettens-vandenBosh, Bult A (1989) Etoposide. In: Florey K (ed) Analytical profiles of drug substances. vol 18. Academic Press, New York, pp 121–151Google Scholar
  28. 28.
    Horton JK, Stevens MFG (1981) A new light on the photodecomposition of the antitumour drug DTIC. J Pharm Pharmacol 33: 808–811Google Scholar
  29. 29.
    Humphreys A, Marty JJ, Gooey SL, Bourne DWF (1978) Stability of methotrexate in an intravenous fluid. Aust J Hosp Pharm 8: 66–67Google Scholar
  30. 30.
    Keller JH, Ensminger WD (1982) Stability of cancer chemotherapeutic agents in a totally implantable drug delivery system. Am J Hosp Pharm 39: 1321–1323Google Scholar
  31. 31.
    Koberda M, Zieske PA, Raghavan NV, Payton RJ (1990) Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers. Am J Hosp Pharm 47: 2528–2529Google Scholar
  32. 32.
    Lokich J, Anderson N, Bern M, Wallach S, Moore C, Williams D Umprayn V (1988) Combined floxuridine and cisplatin in a fourteen day infusion. Cancer 62: 2309–2312Google Scholar
  33. 33.
    Lokich J, Anderson N, Bern M, Wallach S, Moore C, Williams D (1989) Etoposide admixed with cisplatin. Cancer 63: 818–821Google Scholar
  34. 34.
    Lokich J, Bern M, Anderson N, Wallach S, Moore C, Beauchamp K, Williams D (1989) Cyclophosphamide methotrexate, and 5-fluorouracil in a three drug admixture. Cancer 63: 822–824Google Scholar
  35. 35.
    Mariani EP, Southard BJ, Woolever JT, Erlich RH, Granatek AP (1980) Physical compatibility and chemical stability of cisplatin in various diluents and in large volume parenteral solutions. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, Current status and new developments. 1st edn. Academic Press, New York, pp 305–316Google Scholar
  36. 36.
    McElnay JC, Elliott DS, Cartwright-Shamoon J, D'Arcy PF (1988) Stability of methotrexate and vinblastine in burette administration sets. Int J Pharm 47: 239–243Google Scholar
  37. 37.
    Pont LO, Cheung APK, Lin P (1979) Calcium leucovorin. In: Florey K (ed) Analytical profiles of drug substances, vol 8. Academic press, New York, pp 315–350Google Scholar
  38. 38.
    Poochikian GK, Cradock JC, Flora KP (1981) Stability of anthracycline agents in four infusion fluids. Am J Hosp Pharm 38: 483–486Google Scholar
  39. 39.
    Radford JA, Margison JM, Swindell R, Lind MJ, Wilkinson PM, Thatcher N (1990) The stability of ifosfamide in aqeous solution and its suitability for continuous 7-day infusion by ambulatory pumps. Cancer Chemother Pharmacol 26: 144–146Google Scholar
  40. 40.
    Reynolds DL, Sternson LA, Repta AJ (1981) Clinical analysis for the antineoplastic agent, 1,4-dihydroxy-5,8-bis-2-[(2-hydroxyethyl)-amino]-9,10-anthracenedione in plasma. J Chromatogr 222: 225–230Google Scholar
  41. 41.
    Riley CM, Sternson LA (1989) Cisplatin. In: Florey K (ed) Analytical profiles of drug substances, vol 14. Academic Press, New York, pp 77–105Google Scholar
  42. 42.
    Seargeant L, Kobrinsky NL, Sus CJ, Nazeravich DR (1987) In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 71: 1189–1193Google Scholar
  43. 43.
    Sewell GJ, Riley CM, Rowland CG (1987) The stability of carboplatin in ambulatory continuous infusion regimes. J Clin Pharm Ther 12: 427–432Google Scholar
  44. 44.
    Smith JA, Morris A, Duafala ME, Bertino JR, Markman M, Kleinberg M (1989) Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. Am J Hosp Pharm 46: 985–989Google Scholar
  45. 45.
    Stella VJ (1987) Chemical and physical bases determining the instability and incompatibility of formulatd injectable drugs. J Parenter Sci Technol 40: 142–163Google Scholar
  46. 46.
    Stewart CF, Hampton EM (1989) Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 46: 1400–1404Google Scholar
  47. 47.
    Stewart CF, Fleming R (1990) Compatibility of cisplatin and 5-fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 47: 1373–1377Google Scholar
  48. 48.
    Tavoloni N, Guarino AM, Berk PD (1980) Photolytic degradation of Adriamycin. J Pharm Pharmacol 32: 860–862Google Scholar
  49. 49.
    Tomlinson E, Malspeis L (1982) Concomitant adsorption and stability of anthracycline antibiotics. J Pharm Sci 72: 1121–1125Google Scholar
  50. 50.
    Trissel LA, Kleinman LM, Cradock JC, Davignon JP (1979) Investigational drug information: ifosfamide. Drug Intell Clin Pharm 13: 340–341Google Scholar
  51. 51.
    Trissel LA, Flora KP, Vishnuvajjala BR, Davignon JP, Quinn FR (1990) NCI Investigational drugs: Pharmaceutical data 1990. National Institutes of Health, Bethesda, MarylandGoogle Scholar
  52. 52.
    Trissel LA (1990) Handbook on injectable drugs, 6th edn. American Society of Hospital Pharmacy, Bethesda, MarylandGoogle Scholar
  53. 53.
    Vendrig DEMM, Smeets BPGM, Beijnen JH, Houwen OAGJ van der, Holthuis JJM (1988) Degradation kinetics of vinblastine sulphate in aqueous solutions. Int J Pharm 43: 131–138Google Scholar
  54. 54.
    Vendrig DEMM, Beijnen JH, Houwen OAGJ van der, Holthuis JJM (1989) Degradation kinetics of vincristine sulphate and vindesine sulphate in aqueous solutions. Int J Pharm 50: 189–196Google Scholar
  55. 55.
    Vincke BJ, Verstraeten AE, El Eini DID, McCarthy TM (1989) Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm 54: 181–185Google Scholar
  56. 56.
    Walker SE, Lau DWC, DeAngelis C, Iazzetta J, Coons C (1980) Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 43: 265–271Google Scholar
  57. 57.
    Walker SE, Lau DWC, DeAngelis C, Iazzetta J, Coons C (1991) Mitoxantrone stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 44: 143–148Google Scholar
  58. 58.
    Williams DA (1990) Stability and compatibility of admixtures of antineoplastic drugs. In: Lokich J (ed) Cancer Chemotherapy by infusion, 2nd edn. Precept, Chicago, 7Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • David A. Williams
    • 1
  • Jacob Lokich
    • 2
  1. 1.Massachusetts College of Pharmacy and Allied Health SciencesBostonUSA
  2. 2.The Cancer CenterBostonUSA

Personalised recommendations